[go: up one dir, main page]

WO2008024026A3 - Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer - Google Patents

Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer Download PDF

Info

Publication number
WO2008024026A3
WO2008024026A3 PCT/RU2007/000423 RU2007000423W WO2008024026A3 WO 2008024026 A3 WO2008024026 A3 WO 2008024026A3 RU 2007000423 W RU2007000423 W RU 2007000423W WO 2008024026 A3 WO2008024026 A3 WO 2008024026A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxoacridine
acetic acid
prostate cancer
prophylaxis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/RU2007/000423
Other languages
French (fr)
Other versions
WO2008024026A2 (en
Inventor
Kirill Gennadievich Surkov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2008024026A2 publication Critical patent/WO2008024026A2/en
Publication of WO2008024026A3 publication Critical patent/WO2008024026A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides the use of 9-oxoacridine-10-acetic acid, its pharmaceutically acceptable salts and esters, in combination with antiandrogenic hormonotherapy, for the treatment, prophylaxis and relapse prevention of prostate cancer. A method of treatment or prophylaxis of prostate cancer comprises the steps of (a) administration of an effective amount of 9-oxoacridine-10-acetic acid, its pharmaceutically acceptable salt or ester to a patient in need thereof and (b) hormonotherapy aimed at decreasing androgen action. Further, a method of inducing or increasing the sensitivity of prostate cancer to hormone therapy aimed at decreasing androgen action is provided, wherein the method comprises administration of 9-oxoacridine-10-acetic acid, its pharmaceutically acceptable salt or ester.
PCT/RU2007/000423 2006-07-31 2007-07-31 Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer Ceased WO2008024026A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2006127809 2006-07-31
RU2006127809/15A RU2325160C1 (en) 2006-07-31 2006-07-31 Means of treatment and relapse prevention of prostate cancer

Publications (2)

Publication Number Publication Date
WO2008024026A2 WO2008024026A2 (en) 2008-02-28
WO2008024026A3 true WO2008024026A3 (en) 2008-05-29

Family

ID=39107233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2007/000423 Ceased WO2008024026A2 (en) 2006-07-31 2007-07-31 Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer

Country Status (2)

Country Link
RU (1) RU2325160C1 (en)
WO (1) WO2008024026A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2460544C2 (en) * 2010-11-19 2012-09-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ РНИОН Минздравсоцразвития России) Method for assessing clinical effectiveness in prostate cancer
RU2524309C1 (en) * 2013-04-18 2014-07-27 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Method for selecting therapeutic approach to locally advanced prostate cancer
RU2020104475A (en) * 2017-09-27 2021-08-02 Новел Фарма Инк. PALMITIC ACID CONJUGATED PROLONGED GnRH DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING IT
RU2730530C1 (en) * 2019-10-29 2020-08-24 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" New chemical compound of l-lysine 9-oxoacridinyl-10-acetate, stimulating production of interleukin-24 and tumour necrosis factor - beta

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681360A (en) * 1971-04-09 1972-08-01 Hoffmann La Roche Antiviral substituted acridanones
RU2126253C1 (en) * 1996-06-06 1999-02-20 Сурков Кирилл Геннадьевич Agent inducing estrogen and progestine receptors
RU2162843C2 (en) * 1998-05-19 2001-02-10 Закрытое Акционерное Общество "Асгл - Исследовательские Лаборатории" Method of preparing sodium 10-methylene carboxylate-9-acridone or 10- methylenecarboxy-9-acridone from acridone
UA11926U (en) * 2005-07-11 2006-01-16 Volodymyr Volodymyrovy Kilessa Method for immune correction

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536818A1 (en) * 1995-09-20 1997-03-27 Schering Ag Use of beta-interferon to treat patients with prostate cancer
RU2258503C1 (en) * 2004-01-20 2005-08-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Method for treating prostatic cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681360A (en) * 1971-04-09 1972-08-01 Hoffmann La Roche Antiviral substituted acridanones
RU2126253C1 (en) * 1996-06-06 1999-02-20 Сурков Кирилл Геннадьевич Agent inducing estrogen and progestine receptors
RU2162843C2 (en) * 1998-05-19 2001-02-10 Закрытое Акционерное Общество "Асгл - Исследовательские Лаборатории" Method of preparing sodium 10-methylene carboxylate-9-acridone or 10- methylenecarboxy-9-acridone from acridone
UA11926U (en) * 2005-07-11 2006-01-16 Volodymyr Volodymyrovy Kilessa Method for immune correction

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; 1996, SURKOV K G ET AL: "[Neovir, an interferon inductor, modifies expression of steroid hormone receptors in hormone-dependent tissues and restores sensitivity to tamoxifen in patients with inoperable breast cancer]", XP002474585, Database accession no. NLM9123898 *
SZULC B ET AL: "COMPETITION OF SODIUM SALT OF 9-OXO-10-ACRIDINEACETIC ACID WITH ANALOGS DURING INDUCTION OF INTERFERON IN THE MOUSE BONE MARROW-DERIVED MACROPHAGES", ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, POLISH ACADEMY OF SCIENCES, WROCLAW, PL, vol. 33, no. 219, 1985, pages 287 - 297, XP009015170, ISSN: 0004-069X *
SZULC Z ET AL: "SYNTHESIS OF CHOLINE ESTER OF 9-OXO-10-ACRIDINEACETIC ACID AND OF CONGENERS AS POTENTIAL INTERFERON INDUCERS", POLISH JOURNAL OF CHEMISTRY, POLISH CHEMICAL SOCIETY, vol. 60, no. 4-6, 1986, pages 615 - 619, XP009015180 *
TSYRLINA YE V ET AL: "Effect of neoadjuvant therapy with neovir on steroid hormone receptor level in endometrial carcinoma", VOPROSY ONKOLOGII (ST. PETERSBURG), vol. 47, no. 2, 2001, pages 214 - 217, XP009097909, ISSN: 0507-3758 *
VOPROSY ONKOLOGII 1996, vol. 42, no. 6, 1996, pages 28 - 32, ISSN: 0507-3758 *

Also Published As

Publication number Publication date
RU2325160C1 (en) 2008-05-27
WO2008024026A2 (en) 2008-02-28
RU2006127809A (en) 2008-02-10

Similar Documents

Publication Publication Date Title
WO2011119857A3 (en) Intravascular tissue disruption
WO2009129147A3 (en) Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
WO2008075068A3 (en) Acylaminopyrazoles as fgfr inhibitors
WO2009129149A3 (en) Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
WO2008061152A3 (en) Methods and apparatus for performing a non-continuous circumferential treatment to a body lumen
HK1198869A1 (en) Combination treatments for hepatitis c
WO2009129210A3 (en) Compositions and methods for treating post-operative pain using clonidine and bupivacaine
WO2007143600A3 (en) Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
MX2015005798A (en) Combination therapy.
WO2007112357A3 (en) Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
PH12012501358A1 (en) Treatment method
SG141358A1 (en) Treatment of psychiatric patients with reduced heptaic function with paliperidone
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2011050095A3 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
WO2008024026A3 (en) Use of 9-oxoacridine-10-acetic acid, its salts and esters for the treatment, prophylaxis or relapse prevention of prostate cancer
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
HK1255584A1 (en) Combination therapy using acamprosate and d-cycloserine
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
WO2013055913A3 (en) Pgam1 inhibitors and methods related thereto
WO2008001113A3 (en) Use of wnt5a for inhibiting scarring
WO2009047505A3 (en) Dexanabinol with inhibitors of braf or mek for the treatment of melanoma
WO2008121029A3 (en) Use of 9-oxoacridine-10-acetic acid and/or salts and/or its esters thereof for the treatment and prophylaxis of malignant tumors of female reproductive system
WO2011056850A3 (en) Linaclotide for the treatment of chronic constipation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07808751

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07808751

Country of ref document: EP

Kind code of ref document: A2